First quarter
- Sales of
SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK. -
Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in
Americas . - Sales per business area, in local currencies was +12% in Consumables, +8% in Technologies and -12% in Genetics.
- Gross margin increased to 57.1% (56.8).
-
Operating income before depreciation and amortisation (EBITDA) increased to
SEK 272 (262) million, giving an EBITDA margin of 32.4% (30.6). -
Operating cash flow increased to
SEK 198 million (160). -
Net income was
SEK 115 (99) million, resulting in earnings per share ofSEK 0.85 (0.74). -
The product area Genomics was previously reported in Consumables business area but is now part of Genetic Services business area, renamed to Genetics business area.
This disclosure contains information that
Contact:
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
_____________________________________________________________________________________________________________________________________________________________
_____________________________________________________________________________________________________________________________________________________________
https://news.cision.com/vitrolife-ab--publ-/r/interim-report-q1--2024--strong-growth-in-apac-and-solid-margins,c3963367
https://mb.cision.com/Main/1031/3963367/2740767.pdf
(c) 2024 Cision. All rights reserved., source